Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04312347
Study type	Interventional
Source	Nalagenetics Pte Ltd
Contact
Status	Completed
Phase	N/A
Start date	September 6, 2019
Completion date	June 30, 2021

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05534438` - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	Phase 2
	Recruiting	`NCT06064812` - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.	Phase 1
	Completed	`NCT05423730` - Alcohol and Breast Cancer (ABC) Trial	Early Phase 1
	Active, not recruiting	`NCT03983954` - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors	Phase 1
	Completed	`NCT00828854` - Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing	Phase 2
	Recruiting	`NCT05525481` - Tamoxifen Prediction Study in Patients With ER+ Breast Cancer	Phase 4
	Recruiting	`NCT04824014` - 4FMFES-PET Imaging of ER+ Advanced Breast Cancers	Phase 2
	Recruiting	`NCT06395519` - A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	Phase 1
	Recruiting	`NCT04985266` - A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer	Phase 2
	Completed	`NCT00676663` - Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer	Phase 2
	Active, not recruiting	`NCT04551495` - Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)	Phase 2
	Recruiting	`NCT04920708` - Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression	Phase 2
	Not yet recruiting	`NCT06407401` - Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer	Phase 3
	Completed	`NCT01202591` - Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients	Phase 1/Phase 2
	Recruiting	`NCT05490472` - JAB-2485 Activity in Adult Patients With Advanced Solid Tumors	Phase 1/Phase 2
	Completed	`NCT02580448` - CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)	Phase 1/Phase 2
	Recruiting	`NCT04360941` - PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer	Phase 1